Clinical Trial Update: Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Elbasvir/Grazoprevir with and without Sofosbuvir and Ribavirin in cirrhotic Hepatitis C Genotype 3 patients; completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2017-11-13